Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
Date:5/16/2011

CRANBURY, N.J., May 16, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its third quarter ended March 31, 2011.

Recent Highlights

  • Following a meeting with the U.S. Food and Drug Administration (FDA), Palatin submitted a revised protocol to the FDA for initiation of an at-home Phase 2 clinical trial of subcutaneously administered bremelanotide for women with female sexual dysfunction (FSD). This Phase 2 trial for women with FSD is scheduled to start in the second quarter of calendar 2011.
  • Palatin has started discussions with a number of potential development and marketing partners for PL-3994 for acute asthma, which would include the proof-of-concept human trial for asthma using a subcutaneously administered formulation and development of an inhalation formulation.
  • Collaboration compounds licensed pursuant to Palatin's research collaboration and license agreement with AstraZeneca for treatment of obesity, diabetes and related metabolic syndrome have advanced to the clinical stage.
  • In March 2011 Palatin closed on an underwritten public offering resulting in net proceeds of $21.1 million, which should be sufficient to fund projected operations through calendar year 2012.

  • Third Quarter Fiscal 2011 Financial ResultsPalatin reported a net loss of $3.8 million, or $(0.17) per basic and diluted share, for the quarter ended March 31, 2011, compared to a net loss of $2.0 million, or $(0.20) per basic and diluted share for the same period in 2010.  

    The increase in net loss for the quarter ended March 31, 2011, compared to the net loss for the same period last fiscal year, was primarily attributable to a decrease in revenue recognized und
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ) has ... Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... traces its roots in the latter half of ... went unexplored and unfulfilled for several decades owing ...
    (Date:7/10/2014)... of Adelaide research may help in the fight against ... detect tiny quantities of explosives with the use of ... journal Sensors and Actuators B: Chemical , the ... detect explosives in concentrations as low as 6.3 ppm ... only a few minutes. , "Traditionally explosives detection has ...
    (Date:7/10/2014)... Understanding the basis of psychiatric disorders has been extremely ... increase risk but are insufficient to cause disease. Now ... Cell Press journal Cell Stem Cell describe ... genetic risks interact with other risk factors or environmental ... Their research pinpoints a genetic variant that may predispose ...
    (Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
    Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2Even geckos can lose their grip 2
    ... ARI Network Services, Inc., a provider of electronic ... on Wednesday reported increased revenues and record net income for ... for fiscal 2005 were $13.7 million, a 2% increase from ... 67% to $2.1 million or $0.32 per diluted share, from ...
    ... Third Wave Technologies Inc. has filed suit against ... products, the company announced on Tuesday. The suits were filed ... filed suit against Digene Corp., seeking a court ... virus (HPV) products. , ,On Tuesday, Third Wave filed suit ...
    ... Barrett and Milwaukee officials on Wednesday announced plans to ... wireless network accessible to all residents. , ,The Milwaukee ... wireless large city in America, built at no cost ... office. , ,"This initiative constitutes a multi-million dollar private ...
    Cached Biology Technology:Third Wave files patent suits against Digene, Chiron and Bayer 2Milwaukee announces citywide wireless initiative 2
    (Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
    (Date:7/11/2014)... creating a new professorship in tissue engineering to ... Molecular Engineering and the Marine Biological Laboratory, supported ... and Eugene Bell Foundation., The Eugene Bell Professorship ... for Molecular Engineering. That endowed chair holder also ... Eugene Bell Center for Regenerative Biology and Tissue ...
    (Date:7/11/2014)... Standards and Technology (NIST) need a special tool ... prove that necessity is truly the mother of ... Lorna De Leoz and Stephen Stein, NIST chemists ... is the study of the abundant, often-branched sugar ... and lipids and influence cellular processes, including immunity, ...
    Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2
    ... In an Early Edition publication of The Proceedings of ... week, the researchers demonstrate the "alpha-synuclein dance" the switching ... and an extended helix as the surface that it is ... so directly observed in proteins like alpha-synuclein, which are known ...
    ... an extremely effective HIV treatment that keeps virus levels ... virus as some HIV always remains dormant in cells. ... approved as a leukemia drug, has now been shown ... candidate to weed out the hidden virus that HAART ...
    ... 2009 -- Planting soybean on the optimum date produces maximum ... planting date is hard to indentify, because it varies from ... it rains and when it rains. "Planting date ... was introduced into the United States, so there is a ...
    Cached Biology News:Scripps research scientists 'watch' as individual alpha-synuclein proteins change shape 2Scripps research scientists 'watch' as individual alpha-synuclein proteins change shape 3No consistent advantage for planting soybean early 2
    Gastric Carcinoma Marker [BY-1 (3H11)]...
    Human Dectin-1/CLEC7A Biotinylated Affinity Purified PAb...
    Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
    Profilin-1/2 (FL-140)...
    Biology Products: